Global Accelerator for Paediatric Formulations Network (GAP-f)

About us
GAP-f is a WHO Network hosted within the Research for Health Department in the Science Division and was created to respond to the persistent paediatric treatment gap.
Following the resolution at the 69th World Health Assembly on promoting innovation and access to quality, safe, efficacious, and affordable medicines for children, GAP-f was conceived to build on and formalize the model developed within the HIV community—providing a sustainable mechanism to accelerate the development and availability of safer, more effective paediatric formulations.
In 2024, Member States adopted a WHA resolution on Accelerating progress towards reducing maternal, newborn, and child mortality to achieve Sustainable Development Goal targets 3.1 and 3.2. While addressing the broader maternal and child health agenda, the resolution calls for renewed investment in developing and introducing better medicines for children, and recognizes GAP-f as a key collaboration platform. This not only reaffirms GAP-f’s mission but also expands its mandate, highlighting the importance of deeper engagement with Member States.
At GAP-f, children are at the top of our agenda. While significant gains in child health have been achieved—with six million fewer children under five dying in 2016 than in 1990—urgent action is still needed to meet the UN Sustainable Development Goals (SDGs), particularly SDG 3, which aims to ensure healthy lives and promote well-being for all at all ages, including the target to achieve Universal Health Coverage by 2030.
GAP-f would like to thank Digital Medic and its partners for supporting this video.
News
Documents
All →


Accelerating research, development and access to paediatric medicines: Global accelerator...


Shaping the global innovation and access landscape for better paediatric medicines:...
Publications
All →
This third phase of GAP-f’s strategy (2025-2030) focuses on strengthening the global ecosystem for paediatric medicines. With a streamlined approach...

Accelerating the development of priority formulations for antibiotic use in children : target product...
This document summarizes proceedings and outcomes of a technical consultation designed to develop target product profiles for three priority antibiotics...

Accelerating optimal approval of priority formulations for antibiotic use in children: meetings report,...
On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments...

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 mg scored, dispersible tablets,...
Newsletter
GAP-f Newsletter - December 2024
GAP-f Newsletter - July 2023
GAP-f Newsletter - November 2022
GAP-f Newsletter - June 2022
GAP-f Newsletter- November 2021
Subscribe to our newsletter and other updates here.
Events
All →GAP-f Secretariat
John Reeder
Director
Contact
For more information email: